We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLPC:NASDAQPreformed Line Products Company Analysis

Data as of 2026-04-24 - not real-time

$351.17

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Preformed Line Products Company has surged to an all‑time high, driven by a 1‑year price appreciation of well over 100% and a recent breakout to its 52‑week peak. Technical indicators reinforce the momentum: the short‑term moving average sits comfortably above the medium‑term average, the RSI is deep in overbought territory, and the MACD histogram remains positive, all pointing to a bullish trend. Volume, however, is on a downtrend, suggesting that the rally may be losing steam and could be vulnerable to a pullback. The stock’s beta is markedly above the market average, and 30‑day volatility exceeds 50%, underscoring heightened price swings.
Fundamentally, the company trades at a price‑to‑earnings multiple far above the industry norm and well above its discounted cash‑flow estimate, indicating that the market has priced in strong growth expectations. Margins are modest, cash flow is positive but modest relative to debt, and the dividend yield is low with a very conservative payout ratio, supporting dividend sustainability. The blend of aggressive valuation, elevated volatility, and global operational exposure creates a risk profile that leans toward the higher end of the spectrum.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near 52‑week high with bullish technicals
  • Decreasing volume indicating potential short‑term weakness
  • Elevated volatility and beta increasing downside risk

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong growth narrative priced into the stock
  • Modest profitability and cash flow versus debt load
  • Sustained dividend with low payout ratio

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Significant overvaluation relative to fundamentals and DCF
  • High valuation multiples and sector cyclicality
  • Persistent high volatility and beta amplifying market risk

Key Metrics & Analysis

Financial Health

Revenue Growth3.60%
Profit Margin5.27%
P/E Ratio49.3
ROE7.87%
ROA5.57%
Debt/Equity10.04
P/B Ratio3.6
Op. Cash Flow$73.5M
Free Cash Flow$9.2M
Industry P/E31.1

Technical Analysis

TrendBullish
RSI71.2
Support$259.80
Resistance$352.37
MA 20$306.40
MA 50$279.00
MA 200$223.91
MACDBullish
VolumeDecreasing
Fear & Greed Index88.02

Valuation

Fair Value$36.82
Target Price$275.00
Upside/Downside-21.69%
GradeOvervalued
TypeGrowth
Dividend Yield0.25%

Risk Assessment

Beta1.59
Volatility54.97%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.